WO2021072650A1 - Application d'un monocyte intermédiaire dans la préparation d'un médicament pour le diagnostic et la prédiction de la maladie d'alzheimer - Google Patents

Application d'un monocyte intermédiaire dans la préparation d'un médicament pour le diagnostic et la prédiction de la maladie d'alzheimer Download PDF

Info

Publication number
WO2021072650A1
WO2021072650A1 PCT/CN2019/111302 CN2019111302W WO2021072650A1 WO 2021072650 A1 WO2021072650 A1 WO 2021072650A1 CN 2019111302 W CN2019111302 W CN 2019111302W WO 2021072650 A1 WO2021072650 A1 WO 2021072650A1
Authority
WO
WIPO (PCT)
Prior art keywords
monocytes
alzheimer
amyloid peptide
disease
cells
Prior art date
Application number
PCT/CN2019/111302
Other languages
English (en)
Chinese (zh)
Inventor
戴正乾
顾柏俊
黄欣
Original Assignee
湖南乾康科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 湖南乾康科技有限公司 filed Critical 湖南乾康科技有限公司
Priority to PCT/CN2019/111302 priority Critical patent/WO2021072650A1/fr
Priority to CN201980011391.8A priority patent/CN111727260A/zh
Publication of WO2021072650A1 publication Critical patent/WO2021072650A1/fr

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Definitions

  • Amyloid ⁇ peptides on monocytes may have diagnostic value as biomarkers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une application d'un monocyte intermédiaire dans la préparation d'un médicament pour le diagnostic et la prédiction de la maladie d'Alzheimer.
PCT/CN2019/111302 2019-10-15 2019-10-15 Application d'un monocyte intermédiaire dans la préparation d'un médicament pour le diagnostic et la prédiction de la maladie d'alzheimer WO2021072650A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/CN2019/111302 WO2021072650A1 (fr) 2019-10-15 2019-10-15 Application d'un monocyte intermédiaire dans la préparation d'un médicament pour le diagnostic et la prédiction de la maladie d'alzheimer
CN201980011391.8A CN111727260A (zh) 2019-10-15 2019-10-15 中间型单核细胞在制备诊断和预测ad药物中的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/111302 WO2021072650A1 (fr) 2019-10-15 2019-10-15 Application d'un monocyte intermédiaire dans la préparation d'un médicament pour le diagnostic et la prédiction de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
WO2021072650A1 true WO2021072650A1 (fr) 2021-04-22

Family

ID=72563751

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/111302 WO2021072650A1 (fr) 2019-10-15 2019-10-15 Application d'un monocyte intermédiaire dans la préparation d'un médicament pour le diagnostic et la prédiction de la maladie d'alzheimer

Country Status (2)

Country Link
CN (1) CN111727260A (fr)
WO (1) WO2021072650A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573500A (zh) * 2009-08-06 2012-07-11 纽拉尔图斯制药公司 巨噬细胞相关疾病的治疗
CN104011210A (zh) * 2011-10-11 2014-08-27 布里格姆及妇女医院股份有限公司 神经退行性病症中的microRNA
CN104471394A (zh) * 2012-03-26 2015-03-25 耶达研究及发展有限公司 用于诊断阿尔茨海默氏病和用于阿尔茨海默氏病进展的细胞标志物
WO2015185602A1 (fr) * 2014-06-04 2015-12-10 Affiris Ag Traitement et prévention de la maladie de parkinson
CN106413721A (zh) * 2014-05-16 2017-02-15 纽拉尔图斯制药公司 用于治疗巨噬细胞相关病症的方法和组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015165980A2 (fr) * 2014-04-29 2015-11-05 Affiris Ag Traitement et prévention de la maladie d'alzheimer (ad)

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573500A (zh) * 2009-08-06 2012-07-11 纽拉尔图斯制药公司 巨噬细胞相关疾病的治疗
CN104011210A (zh) * 2011-10-11 2014-08-27 布里格姆及妇女医院股份有限公司 神经退行性病症中的microRNA
CN104471394A (zh) * 2012-03-26 2015-03-25 耶达研究及发展有限公司 用于诊断阿尔茨海默氏病和用于阿尔茨海默氏病进展的细胞标志物
CN106413721A (zh) * 2014-05-16 2017-02-15 纽拉尔图斯制药公司 用于治疗巨噬细胞相关病症的方法和组合物
WO2015185602A1 (fr) * 2014-06-04 2015-12-10 Affiris Ag Traitement et prévention de la maladie de parkinson

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GU, B.J. ET AL.: "Innate phagocytosis by peripheral blood monocytes is altered in Alzheimer’s disease", ACTA NEUROPATHOL, vol. 132, 13 July 2016 (2016-07-13), XP036036918, DOI: 10.1007/s00401-016-1596-3 *
YU FENG; LEI LI; XIAO-HONG SUN: "单核细胞和阿尔茨海默病 ; Monocytes and Alzheimer’s disease", NEUROSCIENCE BULLETIN, SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES, HEIDELBERG, vol. 27, no. 2, 6 April 2011 (2011-04-06), Heidelberg, pages 115 - 122, XP019894077, ISSN: 1995-8218, DOI: 10.1007/s12264-011-1205-3 *

Also Published As

Publication number Publication date
CN111727260A (zh) 2020-09-29

Similar Documents

Publication Publication Date Title
Baufeld et al. High-fat diet-induced brain region-specific phenotypic spectrum of CNS resident microglia
Liebner et al. Functional morphology of the blood–brain barrier in health and disease
Wang et al. P2RX7 sensitizes Mac-1/ICAM-1-dependent leukocyte-endothelial adhesion and promotes neurovascular injury during septic encephalopathy
Ghosh et al. Pericytes are involved in the pathogenesis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
Kokona et al. Colony-stimulating factor 1 receptor inhibition prevents disruption of the blood-retina barrier during chronic inflammation
Adams et al. Familial amyloid polyneuropathy
Chan et al. Primary vitreoretinal lymphoma: a report from an international primary central nervous system lymphoma collaborative group symposium
Ruhnau et al. Stroke alters respiratory burst in neutrophils and monocytes
Gruber et al. Targeted GAS6 delivery to the CNS protects axons from damage during experimental autoimmune encephalomyelitis
Singh et al. Functional integrity of synapses in the central nervous system of cognitively intact individuals with high Alzheimer’s disease neuropathology is associated with absence of synaptic tau oligomers
Breen et al. Loss of fractalkine signaling exacerbates axon transport dysfunction in a chronic model of glaucoma
Melero et al. Neutrophil extracellular traps, local IL-8 expression, and cytotoxic T-lymphocyte response in the lungs of patients with fatal COVID-19
Kim et al. Choroid plexus changes on magnetic resonance imaging in multiple sclerosis and neuromyelitis optica spectrum disorder
Winkler et al. Blood-brain barrier resealing in neuromyelitis optica occurs independently of astrocyte regeneration
Dvir-Szternfeld et al. Alzheimer’s disease modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in mouse model of amyloidosis
Wright et al. Patterns of mitochondrial TSPO binding in cerebral small vessel disease: an in vivo PET study with neuropathological comparison
McCann et al. Prevalence of chronic traumatic encephalopathy in the Sydney Brain Bank
Meabon et al. Chronic elevation of plasma vascular endothelial growth factor-A (VEGF-A) is associated with a history of blast exposure
Löscher Epilepsy and alterations of the blood–brain barrier: cause or consequence of epileptic seizures or both?
Qiu et al. Dynamic microglial activation is associated with LPS-induced depressive-like behavior in mice: an [18F] DPA-714 PET imaging study
Teipel et al. Association of CSF sTREM2, a marker of microglia activation, with cholinergic basal forebrain volume in major depressive disorder
WO2021072650A1 (fr) Application d'un monocyte intermédiaire dans la préparation d'un médicament pour le diagnostic et la prédiction de la maladie d'alzheimer
Dong et al. Pro-inflammatory cytokines and leukocyte integrins associated with chronic neuropathic pain in traumatic and inflammatory neuropathies: Initial observations and hypotheses
CN117460956A (zh) 外周血巨噬细胞在制备用于阿尔兹海默病诊断、预后及治疗的试剂和/或药物中的应用
LU503915B1 (en) The application of intermediate mononuclear cells in the preparation of drugs for diagnosis and prediction of AD

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19949368

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19949368

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC